Dicer1 is reduced in APPswe/PSEN1dE9 mice and is regulated by Nrf2

The pathogenesis of Alzheimers disease (AD) involves the central roles of oxidative stress. Oxidative stress due to Dicer1 depletion may underline the neurodegeneration in the central nervous system and degeneration of retinal pigment epithelial cells in geographic atrophy form of age-related macular degeneration. We hypothesized that Dicer1 may play roles in AD pathogenesis. Indeed, Dicer1 was reduced in the hippocampus and cortex of APPswe/PSEN1dE9 mice, an AD model. Dicer1 knockdown induced oxidative stress, mitochondrial dysfunction, apoptosis in cultured neurons, and increased secretions of interleukin-1{beta}/-18, indicators of inflammasome activation. Accordingly, Dicer1 was decreased by amyloid peptide and the effect was connected with down-regulation of nuclear factor erythroid 2-related factor 2 (Nrf2). Anti-oxidant response elements (AREs) were identified in the promoter of Dicer1 and Keap1-Nrf2-AREs signaling was demonstrated to regulate Dicer1 expression. Furthermore, overexpression of Dicer1 carried by adenovirus in the cultured neurons rescued neurite deficit induced by amyloid peptide. In consistent with the in vitro results, injection of Dicer1-overexperssion adenovirus in the hippocampus of the AD mice significantly improved spatial learning. Altogether, we unveiled an unexploited roles of Dicer1 in AD and a novel way of Dicer1 regulation. These findings suggest that Dicer1 may be a target in AD therapy.\n\nSignificance StatementDicer1 is a microRNA-processing enzyme, which is central to microRNA maturation. For the first time, we herein reported that Dicer1 was reduced in the hippocampus or the cortex of AD mice before overt amyloid plque deposition and overexpression of Dicer1 in the hippocampus significantly improved spatial learning in AD mice. We also demonstrated that Dicer1 was regulated by Keap1-Nrf2-ARE signaling which is unreported before. These findings advance understandings of AD pathogenesis and suggest that Dicer1 may be a molecular target in AD therapy.